EndoSphere’s innovative treatments have the potential to help millions of people suffering from serious metabolic diseases such as obesity and type 2 diabetes.
Columbus, OH (PRWEB) May 09, 2012
EndoSphere Inc., a medical technology company that holds 25 issued and pending U.S. and international patents, today announced that the U.S. Patent and Trademark Office has issued the company a new strategic patent containing numerous claims relating to its incisionless antiobesity device technologies.
US patent number 8,147,561 is entitled "Methods and Devices to Curb Appetite and/or Reduce Food Intake." It extends the intellectual property protection for EndoSphere's flagship product, the Satisphere™ System. The SatiSphere device is an endoscopically-insertable device that improves the regulation of appetite and satiety by using the body’s natural physiology. Use of the device does not require any incision and is reversible and repeatable. Clinical studies have shown that the noninvasive device enables obese patients to achieve significant weight loss without invasive surgery or medication.
Worldwide obesity rates have become staggering. According to the Centers for Disease Control (CDC), obesity rates increased so dramatically during the past decade that today, more than 35 percent of U.S. adults suffer from obesity. By comparison, in 2000, not a single U.S. state had an obesity rate above 30 percent. Annual costs attributed to obesity and its co-morbidities are currently estimated at $147 billion and rising.
“This new patent represents a positive endorsement of the quality of EndoSphere’s intellectual property position,” said Christopher Thorne of Broadline Capital, who serves as EndoSphere’s executive chairman. “EndoSphere’s innovative treatments have the potential to help millions of people suffering from serious metabolic diseases such as obesity and type 2 diabetes.”
About EndoSphere Inc.
Founded in 2006, EndoSphere Inc. is a pioneer of endoscopically-insertable medical technologies. The company holds a portfolio of 25 issued and pending U.S. and international patents. Its flagship product, the Satisphere™ System, is a noninvasive treatment for one of the world’s largest health issues: obesity and its co-morbidities. EndoSphere is a portfolio company of Broadline Capital, a global private equity investment firm. Major co-investors include Ohio TechAngel Funds II and III, Co-Investment Fund, Glengary, Millstream Angel Funds, North Coast Angel Fund II, Physician Investment Group, and QCA First Fund III. For more information, please visit http://www.EndoSphereInc.com.